The Use Of UHPLC In Post-Drug Development - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Use Of UHPLC In Post-Drug Development
Ultra high performance liquid chromatography (UHPLC) offers increased performance compared with high performance liquid chromatography (HPLC), including shorter analysis times and increased sensitivity. These features offer many advantages in post-drug development, helping to reduce both the amount of solvent and sample required and, therefore, the associated costs.

Pharmaceutical Technology Europe
Volume 23, Issue 1

What advantages does ultra high performance liquid chromatography (UHPLC) offer over high performance liquid chromatography (HPLC) for excipient/formulation characterisation?

The separation and determination of excipients and the characterisation of formulations are challenging processes because of the complexity and diversity of both the analytes and the sample matrix. Ultra high performance liquid chromatography (UHPLC) offers several advantages over high performance liquid chromatography (HPLC) for these applications. In particular it provides a good combination of speed and resolution; for example, HPLC separations of 15 or 20 min can be conducted in a couple of minutes without compromising resolution.

Using UHPLC systems in combination with columns packed with sub-2 Ám particle diameters, it is possible to make use of increased column efficiencies (i.e., the number of plates per unit of length of column) and, therefore, improve the resolution of the separations in these complex systems as the resolution increases proportionally to the square root of the number of plates. An added advantage of working with UHPLC for excipient/formulation characterisation is the consequent increase in sensitivity per volume of sample injected.

UHPLC is also beneficial for impurity analysis; it improves chromatographic resolution while shortening analytical run times, with a consequent reduction in solvent consumption. In one example, the time required for an assay (analysis of simvastatin tablets) was reduced from 15 min using HPLC to 1 min with UHPLC, significantly increasing throughput and generating savings of more than $35000 per year relating to solvent consumption and disposal.1 Also, as described above, there are advantages in using UHPLC with sub-2 Ám particle packed columns for separations; the amount of sample needed per injection decreases significantly (proportionally to the ratio of the squares of the column diameters and the ratio of the column lengths) compared with the amount normally used in HPLC with columns packed with 2 or 5 Ám particle diameters; for example, a 10 ÁL injection needed in a 25 cm, 4.6 mm I.D column packed with 5 Ám particles can be reduced to less than 1 ÁL when employing a 10 cm, 2.1 mm column packed with sub-2 Ám particles. This can be a crucial advantage in cases where the amount of samples is limited.

What is the role of UHPLC in product quality control?

In quality control, UHPLC provides shorter analysis times, reduced operating costs, and increased sensitivity and separation efficiencies compared with HPLC.1 UHPLC significantly extends the analytical capabilities of HPLC for product quality control by carrying out separations more quickly and reducing the amount of solvent required for determinations. Overall, this reduces the cost associated per sample.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here